Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Purdue scientists: To stop cancer, keep your Icmt away from your Ras

29.03.2004


Halting the development of certain pancreatic, ovarian, colon and lung cancers may be possible with therapy based on recent Purdue University research.


These two images show the development of human cells with (above) and without (below) the normal concentration of the protein Ras in their cell membranes. The cells on the right have the protein Ras scattered throughout their cytoplasm, in contrast with the normally developed cells on the left. The absence of the enzyme Icmt prevents Ras from lodging in the membrane, where it ordinarily performs tasks vital to cellular reproduction. Purdue research suggests that preventing Icmt from interacting with Ras during the protein’s development may inhibit the runaway cell growth that is characteristic of cancer, thus leading to new approaches to treating several forms of the disease. (M. Bergo, Journal of Biological Chemistry)



By investigating a single molecule that influences cell growth, a research group in the Purdue Cancer Center, including Brian S. Henriksen, has gained new insight into the chain of events that make some cancer cells divide uncontrollably – insight that may eventually lead to a way to break that chain, stopping cancer in its tracks. The molecule, known as Icmt, has a critical role in the development of Ras, an ordinarily beneficial protein that tells a cell to divide. The research group has determined how to inhibit Icmt’s influence on Ras, without which the protein cannot develop effectively into an instigator of cell growth.

"A tumor can be seen as cells that forget to stop dividing, and misdeveloped Ras is responsible for some instances of uncontrolled growth," said Henriksen, a graduate student in medicinal chemistry and medical pharmacology in Purdue’s School of Pharmacy. "When Ras develops a mutation, it does its job incorrectly, and it becomes a hazard to the body. Our work with Icmt might lead to therapies that could stop errant Ras from causing tumors to progress."


The research was conducted by an interdisciplinary team from two Purdue departments. Co-directing the team are Christine A. Hrycyna, Walther Assistant Professor in the School of Science’s chemistry department and Richard A. Gibbs, associate professor in the School of Pharmacy’s medicinal chemistry and molecular pharmacology department. Jessica L. Anderson (chemistry) and Henriksen are the principal graduate students involved in the project.

Henriksen will present the group’s results at 6 p.m. Sunday (3/28) at the 227th national meeting of the American Chemical Society in Anaheim, Calif.

Ras is a key protein that signals the body’s cells to begin or cease dividing, but for Ras to develop into its complex final form, it undergoes a lengthy chain of modifications that must play out correctly if the protein is ultimately to function properly.

Ras has long been known to be associated with cancer, as it is the incorrectly modified, or mutated, Ras that is behind the uncontrolled cell growth within many cancers. Ninety percent of all pancreatic cancers, one-half of all colon cancers and one-half of the most virulent lung cancers can be traced back to mutant Ras.

"If you want to fight cancer, controlling Ras is an attractive approach," Gibbs said. "Since it requires a chain of modifications, researchers have long taken the approach that if you break the chain, you can stop the cancer."

Earlier attempts to break the chain have met with difficulty because at the point scientists tried to break it in the past, there was always a "back way" – another chemical "route" the body’s enzymes could take to accomplish a given step in the process. Scientists tried to stop mutant Ras from maturing one way, only to find that they had been circumvented by another enzyme that also could get the job done.

"These troubles were actually a tribute to cellular life’s tenacity and survival techniques," Henriksen said. "Life, cancerous life included, will often find a way to overcome adversity. That is why we are so excited about Icmt – it seems to be a weak link in the chain."

The enzyme Icmt, short for isoprenyl cysteine methyltransferase, represents a link in the chain that is a bottleneck of sorts, as there appears to be no back way available to form Ras if Icmt is not present at the right point in the process. Specifically, Icmt’s task – a process called methyl esterification – is to add a small chemical "cap," called a methyl group, to the larger Ras molecule. Without this methyl cap, Ras is unable to anchor itself in the plasma membrane that surrounds a cell, where it must lodge if it is to effect growth commands. So Gibbs and Hrycyna’s labs joined forces to block the biochemical activity of Icmt with small drug molecules, preventing the methyl esterification of Ras and effectively breaking its ability to localize to the plasma membrane.

"This effort depended on both labs," Anderson said. "The Gibbs laboratory brought synthetic expertise, and the Hrycyna laboratory brought large quantities of the protein and the expertise to assay the effects of the inhibitors."

Other groups have shown recently that this lack of a methyl cap causes Ras to localize in the wrong region of the cell and, importantly, results in a Ras protein that cannot support cancerous growth.

"These findings are terrific news for our efforts," said Hrycyna. "If our inhibitor molecules directed at stopping or slowing the activity of Icmt in tumor cells are effective, we should be able to stop the growth of Ras-based cancers."

Hrycyna said she believed the discovery could ultimately throw a wrench into cancer’s operation, but that it was still too early to predict victory.

"We have succeeded in stopping Ras at the protein level and are just beginning to work with whole cells," she said. "This is very different from getting results in animals, and we’re still a long way from human trials. No one should look for this to cure cancer anytime soon, though we are extremely encouraged by these initial results."

But to move the process toward the goal of curing cancer, the group plans to look into other ways of altering Icmt to increase the effect.

"Other ways of changing Icmt might make it even more potent at stopping the development of Ras," Henriksen said. "We’d like to look at all our options and combine them into the most potent inhibitor we can manage – that’s a good goal for the near future."

This research is sponsored in part by a collaborative grant to Gibbs and Hrycyna by the Indiana Elks and the Purdue Cancer Center.

The research group is associated with the Purdue Cancer Center. One of just eight National Cancer Institute-designated basic research facilities in the United States, the center attempts to help cancer patients by identifying new molecular targets and designing future agents and drugs for effectively detecting and treating cancer.

Writer: Chad Boutin, (765) 494-2081, cboutin@purdue.edu

Sources: Brian S. Henriksen, (765) 496-2727, loxarr@hotmail.com
Christine Hrycyna, (765) 494-7322, hrycyna@purdue.edu
Richard Gibbs, (765) 494-1456, rgibbs@purdue.edu
Jessica Anderson, jeanders@purdue.edu

Purdue News Service: (765) 494-2096; purduenews@purdue.edu

Chad Boutin | Purdue News
Further information:
http://news.uns.purdue.edu/html4ever/2004/040328.Henriksen.ras.html

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

New gene catalog of ocean microbiome reveals surprises

18.08.2017 | Life Sciences

Astrophysicists explain the mysterious behavior of cosmic rays

18.08.2017 | Physics and Astronomy

AI implications: Engineer's model lays groundwork for machine-learning device

18.08.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>